These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 33038669

  • 21. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
    Kotch C, Avery R, Getz KD, Bouffet E, de Blank P, Listernick R, Gutmann DH, Bornhorst M, Campen C, Liu GT, Aplenc R, Li Y, Fisher MJ.
    Neuro Oncol; 2022 Aug 01; 24(8):1377-1386. PubMed ID: 35018469
    [Abstract] [Full Text] [Related]

  • 22. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.
    Kinori M, Armarnik S, Listernick R, Charrow J, Zeid JL.
    Am J Ophthalmol; 2021 Jan 01; 221():91-96. PubMed ID: 32283094
    [Abstract] [Full Text] [Related]

  • 23. Evaluation of optic nerve diameters in individuals with neurofibromatosis and comparison of normative values in different pediatric age groups.
    Tosun M, Güngör M, Uslu H, Anık Y.
    Clin Imaging; 2022 May 01; 85():83-88. PubMed ID: 35259715
    [Abstract] [Full Text] [Related]

  • 24. Neurofibromatosis Type 1: Description of a Novel Diagnostic Scoring System in Pediatric Optic Nerve Glioma.
    Eid H, Crevier-Sorbo G, Aldraihem A, Menegotto F, Wilson N.
    AJR Am J Roentgenol; 2019 Apr 01; 212(4):892-898. PubMed ID: 30741560
    [Abstract] [Full Text] [Related]

  • 25. Neurofibromatosis type 1-associated optic pathway gliomas: pathogenesis and emerging treatments.
    Amato A, Imbimbo BP, Falsini B.
    Eur Rev Med Pharmacol Sci; 2023 Jun 01; 27(12):5636-5653. PubMed ID: 37401302
    [Abstract] [Full Text] [Related]

  • 26. Neurofibromatosis type 1 and sporadic optic gliomas.
    Singhal S, Birch JM, Kerr B, Lashford L, Evans DG.
    Arch Dis Child; 2002 Jul 01; 87(1):65-70. PubMed ID: 12089128
    [Abstract] [Full Text] [Related]

  • 27. Clinical Presentation and Outcome of Patients With Optic Pathway Glioma.
    Robert-Boire V, Rosca L, Samson Y, Ospina LH, Perreault S.
    Pediatr Neurol; 2017 Oct 01; 75():55-60. PubMed ID: 28847625
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
    Fisher MJ, Loguidice M, Gutmann DH, Listernick R, Ferner RE, Ullrich NJ, Packer RJ, Tabori U, Hoffman RO, Ardern-Holmes SL, Hummel TR, Hargrave DR, Bouffet E, Charrow J, Bilaniuk LT, Balcer LJ, Liu GT.
    Neuro Oncol; 2012 Jun 01; 14(6):790-7. PubMed ID: 22474213
    [Abstract] [Full Text] [Related]

  • 30. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
    Segal L, Darvish-Zargar M, Dilenge ME, Ortenberg J, Polomeno RC.
    J AAPOS; 2010 Apr 01; 14(2):155-8. PubMed ID: 20451859
    [Abstract] [Full Text] [Related]

  • 31. Growth hormone excess in children with neurofibromatosis type-1 and optic glioma.
    Cambiaso P, Galassi S, Palmiero M, Mastronuzzi A, Del Bufalo F, Capolino R, Cacchione A, Buonuomo PS, Gonfiantini MV, Bartuli A, Cappa M, Macchiaiolo M.
    Am J Med Genet A; 2017 Sep 01; 173(9):2353-2358. PubMed ID: 28631895
    [Abstract] [Full Text] [Related]

  • 32. [Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children].
    Florent C, Beylerian M, Mairot K, Dambricourt L, André N, David T, Girard N, Audic F, Denis D.
    J Fr Ophtalmol; 2022 Feb 01; 45(2):173-184. PubMed ID: 34972579
    [Abstract] [Full Text] [Related]

  • 33. Precocious and accelerated puberty in children with neurofibromatosis type 1: results from a close follow-up of a cohort of 45 patients.
    Pinheiro SL, Maciel J, Cavaco D, Figueiredo AA, Damásio IL, Donato S, Passos J, Simões-Pereira J.
    Hormones (Athens); 2023 Mar 01; 22(1):79-85. PubMed ID: 36269545
    [Abstract] [Full Text] [Related]

  • 34. Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type 1.
    Freret ME, Gutmann DH.
    J Neurosci Res; 2019 Jan 01; 97(1):45-56. PubMed ID: 29704429
    [Abstract] [Full Text] [Related]

  • 35. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1.
    Moharir M, London K, Howman-Giles R, North K.
    Eur J Nucl Med Mol Imaging; 2010 Jul 01; 37(7):1309-17. PubMed ID: 20179923
    [Abstract] [Full Text] [Related]

  • 36. Clinical signs and genetic evaluation of patients with neurofibromatosis type 1 with and without optic pathway gliomas in a center in Turkey.
    Sharafi P, Varan A, Ersoy-Evans S, Ayter S.
    Childs Nerv Syst; 2024 Feb 01; 40(2):511-515. PubMed ID: 37401974
    [Abstract] [Full Text] [Related]

  • 37. Comparison of multi-shot and single shot echo-planar diffusion tensor techniques for the optic pathway in patients with neurofibromatosis type 1.
    Ho CY, Deardorff R, Kralik SF, West JD, Wu YC, Shih CS.
    Neuroradiology; 2019 Apr 01; 61(4):431-441. PubMed ID: 30684113
    [Abstract] [Full Text] [Related]

  • 38. Optic pathway glioma in children: 10 years of experience in a single institution.
    Doganis D, Pourtsidis A, Tsakiris K, Baka M, Kouri A, Bouhoutsou D, Varvoutsi M, Servitzoglou M, Dana H, Kosmidis H.
    Pediatr Hematol Oncol; 2016 Mar 01; 33(2):102-8. PubMed ID: 27007263
    [Abstract] [Full Text] [Related]

  • 39. Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children.
    Ullrich NJ, Prabhu SP, Packer RJ, Goldman S, Robison NJ, Allen JC, Viskochil DH, Gutmann DH, Perentesis JP, Korf BR, Fisher MJ, Kieran MW, NF Clinical Trials Consortium.
    Pediatr Blood Cancer; 2021 Apr 01; 68(4):e28833. PubMed ID: 33336845
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.